• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

    3/18/25 4:32:00 PM ET
    $IMVT
    $ROIV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMVT alert in real time by email

    NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.

    Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.

    Webcast Details

    The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call.

    About Roivant

    Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or "Vants" to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.

    Contacts:

    Investors

    Keyur Parekh

    [email protected]

    Media

    Stephanie Lee

    [email protected]



    Primary Logo

    Get the next $IMVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMVT
    $ROIV

    CompanyDatePrice TargetRatingAnalyst
    Immunovant Inc.
    $IMVT
    3/3/2025$20.00Hold
    Jefferies
    Immunovant Inc.
    $IMVT
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    Immunovant Inc.
    $IMVT
    10/10/2024$36.00Outperform
    Raymond James
    Immunovant Inc.
    $IMVT
    10/9/2024$47.00 → $53.00Outperform
    Oppenheimer
    Immunovant Inc.
    $IMVT
    3/28/2024$50.00Outperform
    Oppenheimer
    Immunovant Inc.
    $IMVT
    3/13/2024$50.00Buy
    Goldman
    Immunovant Inc.
    $IMVT
    2/20/2024$51.00Overweight
    JP Morgan
    Roivant Sciences Ltd.
    $ROIV
    2/15/2024$17.00Outperform
    Wolfe Research
    More analyst ratings

    $IMVT
    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Immunovant Sciences with a new price target

      Jefferies initiated coverage of Immunovant Sciences with a rating of Hold and set a new price target of $20.00

      3/3/25 7:24:04 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Sciences downgraded by Wolfe Research

      Wolfe Research downgraded Immunovant Sciences from Outperform to Peer Perform

      1/3/25 7:34:55 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on Immunovant Sciences with a new price target

      Raymond James resumed coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $36.00

      10/10/24 8:38:30 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    $ROIV
    SEC Filings

    See more
    • SEC Form 144 filed by Roivant Sciences Ltd.

      144 - Roivant Sciences Ltd. (0001635088) (Subject)

      5/7/25 4:37:34 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Roivant Sciences Ltd.

      144 - Roivant Sciences Ltd. (0001635088) (Subject)

      5/6/25 4:21:17 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Immunovant Inc.

      S-8 - Immunovant, Inc. (0001764013) (Filer)

      4/30/25 4:06:19 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ramaswamy Vivek sold $10,129,810 worth of shares (898,959 units at $11.27), decreasing direct ownership by 2% to 39,174,611 units (SEC Form 4)

      4 - Roivant Sciences Ltd. (0001635088) (Issuer)

      5/8/25 8:51:50 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Girao Tiago was granted 208,388 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:09 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Susman Robert Graham was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:05 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepointsINDs active for both MG and CIDP wi

      3/19/25 7:45:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMVT
    $ROIV
    Leadership Updates

    Live Leadership Updates

    See more
    • Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

      Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

      9/23/24 8:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

      NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

      3/26/24 6:22:00 PM ET
      $PGTI
      $ROIV
      $RUN
      $SPGI
      Building Products
      Industrials
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

      BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

      11/10/23 8:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMVT
    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/14/24 4:31:06 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

      SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 4:58:58 PM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Roivant Sciences Ltd.

      SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

      11/12/24 10:34:18 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMVT
    $ROIV
    Financials

    Live finance-specific insights

    See more
    • Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

      Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registrational program for IMVT-1402 in SjD, its fifth and potentially best-in-class indication with positive in-class competitor data from Phase 2 studies suggesting a correlation between depth of IgG reduction and degree of clinical improvement; study expected to initiate in summer 2025Proof-of-concept study of

      4/21/25 7:00:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction) Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70% In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepoints INDs active for both MG and C

      3/19/25 7:45:00 AM ET
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $IMVT
    $ROIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      1/15/25 4:36:38 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      10/4/23 5:15:20 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care